Astrid Maria Westendorf

Astrid Maria Westendorf

Auto-generated profile, based on publicly available information

Astrid Maria Westendorf

Institute of Medical Microbiology, University Hospital Essen, University Duisburg-Essen

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2019 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
EPEva Pastille
Eva Pastille
MWMarie-Hélène Wasmer
Marie-Hélène Wasmer
AAAlexandra Adamczyk
Alexandra Adamczyk
VVVivian P. Vu
Vivian P. Vu
LMLukas F. Mager
Lukas F. Mager
PKPhilippe Krebs
Philippe Krebs
The composition of immune infiltrates strongly affects the prognosis of patients with colorectal cancer (CRC). Interleukin (IL)-33 and regulatory T cells (Tregs) in the tumor microenvironment have been separately implicated in CRC; however their contribution to intestinal carcinogenesis is still controversial. Here, we reveal that IL-33 signaling promotes CRC by changing the phenotype of Tregs. In mice with CRC, tumor-infiltrating Tregs preferentially upregulate IL-33 receptor (ST2), and IL-33/ST2 signaling positively correlates with tumor number and size. Transcriptomic and flow cytometry analyses demonstrate that ST2 expression induces a more activated and migratory phenotype in FOXP3+ Tregs, which favors their accumulation in the tumor environment. Consequently, genetic ablation of St2 reduces Treg infiltration and concomitantly enhances the frequencies of effector CD8+ T cells, thereby restraining CRC. Mechanistically, IL-33 curtails IL-17 production by FOXP3+ Tregs and inhibits Th17 differentiation. In humans, numbers of activated ST2-expressing Tregs are increased in blood and tumor lesions of CRC patients, suggesting a similar mode of regulation. Together, these data indicate a central role of IL-33/ST2 signaling in shaping an immunosuppressive environment during intestinal tumorigenesis. Blockade of this pathway may provide a strategy to modulate the composition of CRC immune infiltrates.


1 January 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
AFAnnika Frede
Annika Frede
BNBernhard Neuhaus
Bernhard Neuhaus
RKRobert Klopfleisch
Robert Klopfleisch
CWCatherine Walker
Catherine Walker
JBJan Buer
Jan Buer
AWAstrid M. Westendorf
Astrid M. Westendorf

13 August 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
EPEva Pastille
Eva Pastille
KBKatrin Bardini
Katrin Bardini
DFDiana Fleissner
Diana Fleissner
AAAlexandra Adamczyk
Alexandra Adamczyk
AFAnnika Frede
Annika Frede
AWAstrid M. Westendorf
Astrid M. Westendorf
Regulatory T cells (Treg) are supportive to cancer development in most tissues, but their role in colitis-associated colon cancer (CAC) remains unclear. In this study, we investigated the role of CD4+Foxp3+ Treg in a mouse model of CAC and in patients with colon cancer. These Treg were increased strongly in number in a mouse model of CAC and in the peripheral blood of patients with colon cancer, exhibiting an activated phenotype as defined by elevated expression of GARP, CD103, CTLA-4, and IL10, along with an increased suppressive effect on the proliferation and Th1 cytokine expression of CD4+CD25− responder T cells ex vivo. Transient ablation of CD4+Foxp3+ Treg during tumor development in the CAC model suppressed tumor outgrowth and distribution, accompanied by an increased number of CD8+IFNγ/granzyme B-producing effector T cells. Conversely, inactivation of IL10 in Treg did not elevate the antitumor response but instead further boosted tumor development. Our results establish a tumor-promoting function for Treg during CAC formation, but they also suggest that a selective, transient ablation of Treg can evoke antitumor responses, with implications for immunotherapeutic interventions in patients with CAC. Cancer Res; 74(16); 4258–69. ©2014 AACR.

2 October 2008 in Gut
Verified
Journal Article
Closed access
PDF file
AWA M Westendorf
A M Westendorf
DFD Fleissner
D Fleissner
LGL Groebe
L Groebe
SJS Jung
S Jung
AGA D Gruber
A D Gruber
JBJan Buer
Jan Buer
Background: Regulatory T cells (T regs ) have potential anti-inflammatory effects and are likely to be important in the pathogenesis of chronic inflammatory bowel disease (IBD). However, the induction and expansion of T regs at sites of mucosal inflammation are not yet fully understood and may involve antigen presentation by local dendritic cells (DCs) and/or intestinal epithelial cells (IECs). Methods: To determine the unique ways in which the gut induces or expands T regs , a transgenic mouse model that is based on the specific expression of a model autoantigen (influenza haemagglutinin (HA)) in the intestinal epithelium (VILLIN-HA) was used. Gut-associated DCs and IECs isolated from these mice were phenotypically and functionally characterised for the potential to interact with HA-specific T regs in vitro and in vivo. Results: Intestinal self-antigen expression leads to peripheral expansion of antigen-specific CD4 + Foxp3 + T regs . Although gut-associated DCs can induce antigen-specific CD4 + Foxp3 + T cell proliferation, in vivo depletion of DCs did not preclude proliferation of these cells. Interestingly, antigen presentation by primary IECs is sufficient to expand antigen-specific CD4 + Foxp3 + T regs efficiently. This is dependent on major histocompatibility complex class II, but, in contrast to DCs, is unlikely to require transforming growth factor β and retinoic acid. Conclusion: This study provides experimental evidence for a new concept in mucosal immunity: in contrast to current thinking, expansion of T regs can be achieved independently of local DCs through antigen-specific IEC–T cell interactions.

1 December 2005 in Diabetes
Verified
Journal Article
Open access
PDF file
DBDunja Bruder
Dunja Bruder
AWAstrid M. Westendorf
Astrid M. Westendorf
WHWiebke Hansen
Wiebke Hansen
SPSilvia Prettin
Silvia Prettin
AGAchim D. Gruber
Achim D. Gruber
JBJan Buer
Jan Buer
Targeting of antigens to immature dendritic cells has been shown to result in antigen-specific T-cell tolerance in vivo. In the INS-HA/TCR-HA transgenic mouse model for type 1 diabetes, we tested the potential of the dendritic cell–specific monoclonal antibody DEC-205 conjugated to the hemagglutinin (HA) antigen (DEC-HA) to prevent disease onset. Whereas untreated INS-HA/TCR-HA mice all develop insulitis, and ∼40% of these mice become diabetic, repeated injection of newborn mice with DEC-HA protected almost all mice from disease development. Histological examination of the pancreata revealed significant reduction of peri-islet infiltrations in DEC-HA–treated mice, and the islet structure remained intact. Moreover, HA-specific CD4+ T-cells from anti–DEC-HA–treated INS-HA/TCR-HA mice exhibited increased expression of Foxp3, cytotoxic T-lymphocyte–associated antigen-4, and the immunosuppressive cytokines interleukin-10 and transforming growth factor-β. The findings indicate that targeting of the HA antigen to immature dendritic cells in vivo leads to a relative increase of antigen-specific Foxp3+ regulatory T-cells that suppress the development of type 1 diabetes. Our results provide a basis for the development of novel strategies focusing on prevention rather than treatment of autoimmune diseases.